Experts at the University of Washington and other colleges warn that patients seeking alternative allergy treatments should not quit standard medications.
The Asthma and Allergy Foundation of America estimates that 40 percent of U.S. citizens have tried alternative medicine and doctors say patients are increasingly asking about alternative treatments for seasonal allergies, USA Today reported Thursday.
However, medical experts warn that abandoning scientifically proven forms of treatment in favor of untested alternative methods could be dangerous.
"Anyone with moderate to severe allergies and asthma should absolutely remain on standard, conventional forms of medication. Asthma in particular is a potentially life-threatening condition, especially in children," said Barak Gaster, associate professor of medicine at the University of Washington.
Michael Zacharisen, associate professor at The Medical College of Wisconsin in Milwaukee said alternative allergy treatments are largely lacking in scientific data to back them up.
"There is not good, rigorous scientific research showing that they are effective and safe for allergies and asthma," he said.
Copyright 2007 by United Press International
Related stories:
Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
A patient’s expectations about the side effects of chemotherapy usually focus on nausea, hair loss, fatigue and other side effects. Worries about severe allergic reactions to their therapy is usually not a concern.
European scientists call for more systematic diagnosis of aspirin hypersensitivity
A position paper on the diagnosis of aspirin hypersensitivity by a team of European scientists from the Global Allergy and Asthma European Network (GA
2LEN) has just been published on the Allergy Journal website. Designed for health professionals, the guidelines propose detailed protocols for challenge tests. The paper is endorsed by the European Academy of Allergology and Clinical Immunology (EAACI) and GA
2LEN partners.
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.
NIAID will not move forward with the PAVE 100 HIV Vaccine Trial
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.
Some drugs increase risk of falling
Researchers at the University of North Carolina at Chapel Hill have created a list of prescription drugs that increase the risk of falling for patients aged 65 and older who take four or more medications on a regular basis.
Study finds unique HIV vaccine formula elicits strong immune responses
Today, Advanced BioScience Laboratories, Inc. and the University of Massachusetts Medical School report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
Newly refined antibody therapy may be potent treatment for autoimmune diseases
An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation by Rockefeller University researchers. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors.
Smallpox vaccine alternative identified
University of California, Irvine infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus.